



PRESS RELEASE

Crucell Nominates Steve Davis as Supervisory Board Member

Leiden, The Netherlands, 30 January 2008 - Dutch biotechnology company Crucell N.V. today announced the nomination of Mr. Steve Davis to join its Supervisory Board. The Supervisory Board will propose to Crucell's shareholders to appoint Mr. Davis as member of the Supervisory Board at the company's AGM, May 30, 2008.

Mr. Davis (1957) was CEO of Corbis Corporation until 2007 and now acts as a senior advisor to the company. Corbis is a global digital media business privately owned by Bill Gates. During Mr. Davis' 10-year tenure as CEO of Corbis Corporation, he oversaw the development of the company from an Internet start-up to an established global leader with annual revenues of over US\$ 250 million and with more than 1100 employees. Prior to his role as CEO, Mr. Davis held several roles at Corbis as Corporate Attorney, VP Strategy Development and General Council.

Mr. Davis also worked as an attorney at Seattle-based Preston Gates & Ellis, specializing in intellectual property. He has held positions within the United Nations High Commissioner for Refugees and several refugee resettlement programs.

Mr. Davis currently is a member of the Board of Trustees and Chair of the Leadership Council for PATH, a non-profit organization focused on improving public health in the developing world and one of the largest recipients of funds from the Bill & Melinda Gates Foundation. He is a member of the Board of Trustees, Chair of the Tech Transfer Committee and Executive Committee/Board Secretary for the Fred Hutchinson Cancer Research Center, one of the largest cancer (and infectious diseases) research centers in the world. Other organizations where Mr. Davis holds a board position include Intrepid Learning Solutions, Seattle Foundation, and PlanetOut Inc. He is also a member of the Council of Foreign Relations. Mr. Davis has held board positions of a number of other organizations including Npower and the Washington State Technology Alliance.

Mr. Davis holds a Bachelor of Arts from Princeton University, a Master of Arts from the University of Washington and a Doctorate in Law from Columbia University School of Law.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral



cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad pipeline, with several products based on its unique PER.C6® production technology in development. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Media:

Barbara Mulder
Director Corporate Communications
Tel: +31-(0)71-519 7346
press@crucell.com

Investors/Analysts:

Oya Yavuz
Director Investor Relations
Tel: +31-(0)71-519 7064
ir@crucell.com